CVRx, Inc. Provides Earnings Guidance for Second Quarter and Full Year of 2024
April 30, 2024 at 04:05 pm EDT
Share
CVRx, Inc. provided earnings guidance for the second quarter and full year of 2024. For the period, the company expects Total revenue between $50.0 million and $53.0 million.
For the full year, the company expects to report total revenue between $11.3 million and $12.3 million.
CVRx, Inc. is a commercial-stage medical device company. The Company is focused on developing, manufacturing and commercializing advanced neuromodulation solutions for patients with cardiovascular diseases. The Company's integrated platform technology, Barostim, is designed to leverage the power of the brain and nervous system to address the imbalance of the autonomic nervous system (ANS), which causes heart failure with reduced ejection fraction (HFrEF) and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy (BAT) by sending imperceptible and persistent electrical pulses to baroreceptors located in the wall of the carotid artery to signal the brain to modulate cardiovascular function. Barostim is a minimally invasive neuromodulation device that consists of two implantable components, an implantable pulse generator (IPG) and a stimulation lead, and is programed by a wireless clinician-controlled programmer that communicates with the IPG.